Openbookopenbook
Equity
Hard to Treat Diseases Inc(HTDS)
USD --+0.00%
Reward67High
Risk24Low
📊75%Data
Strong 16% profit margin
HTDS
+0.0 · +0.00%
USD · OTCCE
Hard to Treat Diseases Inc | Healthcare
Growth Machine
Market Cap:109646
ℹ️
Reward Rating
67
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
24
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on HTDS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Hard to Treat Diseases Inc?

manufactures, supplies, and exports human vaccines and biological products in China and internationally.

HTDS · Verdict

Solid reward · low risk

HTDS stands out on growth and balance sheet, but watch the profitability signal.

Based on 88% data coverage

HTDS · Verdict

What’s working & what to watch

Strengths 4

  • Growth92/100

    Revenue +7432.1% CAGR

  • Balance sheet84/100

    Current ratio 1.60

  • Cash flow82/100

    12% net margin

  • Volatility80/100

    Top decile vs peers

Watchouts 1

  • Profitability40/100

    12% net margin · 0% ROE

Model-based scoring. For information only — not financial advice.

What is Hard to Treat Diseases Inc?

manufactures, supplies, and exports human vaccines and biological products in China and internationally. The company offers human vaccines, such as recombinant human papillomavirus bivalent, freeze-dried live attenuated hepatitis A, recombinant hepatitis E, meningococcal polysaccharide, 23-valent pneumococcal polysaccharide, varicella, rabies, group ACYW135meningococcal conjugate, inactivated poliomyelitis, enterovirus Type 71, influenza, meningococcal Group A, C bivalent polysaccharide conjugate, recombinant hepatitis B, poliomyelitis, and pneumococcal polysaccharide conjugate vaccines. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 109.65K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Profitability metrics are mixed — margins may be under pressure.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: High (67)

The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap109.65K
P/E RatioN/A
Dividend YieldN/A
52 Week HighN/A
52 Week LowN/A
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding5B
No. of EmployeesN/A
IndustryBiotechnology
ExchangeOTCCE
Beta0.416
CurrencyUSD
Websitewww.mellowhope.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.